Opportunity
SAM #26-005075
Sole Source Maintenance Agreement for Illumina NextSeq 1000 Sequencing System at NIH Clinical Center
Buyer
NIH Office of Logistics and Acquisition Operations
Posted
May 01, 2026
Respond By
May 10, 2026
Identifier
26-005075
NAICS
339112, 811219
NIH's Department of Transfusion Medicine at the Clinical Center is seeking a sole source maintenance agreement for its Illumina NextSeq 1000 Sequencing System. - Agency: National Institutes of Health (NIH), Office of Logistics and Acquisition Operations (OLAO) - Department: Department of Transfusion Medicine (DTM), NIH Clinical Center - Sole source vendor: Illumina, Inc. (OEM) - Product: NextSeq 1000 Sequencing System - Service: Maintenance agreement for the sequencing instrument - Justification: Only Illumina, Inc. can provide OEM maintenance; no other vendors considered - Procurement method: FAR Part 13 Simplified Acquisition Procedures - Classification: PSC 6515 (Medical Instruments), NAICS 339112 (Medical Instrument Manufacturing) - Place of performance: NIH Clinical Center, Bethesda, MD 20892 - No competing vendors or products identified - No product line items; only maintenance service required
Description
This acquisition is for a maintenance agreement for the Illumina NextSeq 1000 Sequencing System at the Department ofTransfusion Medicine (DTM) at the National Institutes ofHealth (NIH) Clinical Center (CC).
• Product Service Code: 6515 – Medical Instruments,Equipment, and Supplies • NAICS Code: 339112 – Surgical and Medical Instrument Manufacturing • Place of Performance: Bethesda, MD 20892 USA POTS: 26-005075
This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested.
The National Institutes of Health (NIH) intends to award afixed price purchase order to Illumina, Inc., located at 5200 Illumina Way, San Diego, CA 92122, on a firm fixed price sole source award basis to provide the Illumina NextSeq 1000 Sequencing System at the National Institutes of Health, Department of Transfusion Medicine (DTM).
The instrument is manufactured and serviced by the vendor. The equipment is required by the original manufacturer (Illumina, Inc.) and it is therefore deemed to be in the Government’s best interest that this item is procured from the manufactuer.
This acquisition is being conducted using policies unique tothe Federal Acquisition Regulation (FAR) Part 13 – SimplifiedAcquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold(SAT), contracting officers may solicit from one source if thecontracting officer determines that the circumstance of thecontract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified AcquisitionProcedures are exempt from the requirements of FAR Part 6-Competition Requirements.
Interested parties may identify their interest and capabili-ties in response to this posting. The determination by the Government not to compete the proposed requirementbased upon responses to this notice is solely within the discretion of the Government.
Comments to this announcement, referencing this postingnumber, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing datespecified in this announcement, to the attention of Gregory Noland, Contract Specialist via email to gregory.noland@nih.gov by May 10, 2026 at 1600 EST.